PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Julian Panés  ¹     Remo Panaccione  ²     Geert R. D'Haens  ³     Chenglong Han  ⁴     Susana Gonzalez  ⁵     Kathleen Weisel  ⁵     Mary Elleen Frustaci  ⁵     Zijiang Yang  ⁵     Jewel Johanns  ⁵     Matthew Germinaro  ⁵     Silvio Danese  ⁶     Bruce E. Sands  ⁷     David T. Rubin  ^8    
1 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
² University of Calgary, Calgary, Canada
³ Amsterdam UMC, Amsterdam, Netherlands
⁴ Janssen Global Services, LLC, Malvern, United States
⁵ Janssen Research & Development, LLC, Spring House, United States
⁶ Humanitas Research Hospital, Milan, Italy
⁷ Icahn School of Medicine at Mount Sinai, New York, United States
⁸ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)